Slide 1: Managing Director's Report 12 Months to 31 July 2016
For personal use only Managing Director’s Report 12 Months to 31 July 2016 21 September 2016
Slide 2: Vision and Mission Statement
For personal use only Vision and Mission Statement Vision To optimise the health and development of adults, infants and children. Mission To deliver science based bioactives which provide health benefits to adults, infants, children and to the medical food markets. 1
Slide 3: Full Year Performance Highlights
For personal use only Full Year Performance Highlights Total Revenue Strong growth in $42.9m up 43% non-traditional accounts & driven by improved demand pipeline of new opportunities Net Profit $2.2m up Inventory managed at on 2015 $0.1m $13.6m down 4% on prior year Operating expenses Balance
Slide 4: Full Year 2016 Results
For personal use only Full Year 2016 Results AUD million 4E Reported 4E Reported 43% year on year revenue 31 Jul 2016 31 Jul 2015 growth Revenue $42.9 $29.9 Increased sales to EU & ANZ EBITDA $3.3 $0.6 and new customers EBIT $2.8 ($0.1) EBIT $2.8m (PCP -$0.1m) NPBT $3.1 nil Fixed costs manag
Slide 5: Balance Sheet July 2016
For personal use only Balance Sheet 31 July 2016 AUD million Reported Reported Movement Cash balance 31 July 2016 31 July 2015 strong $8.2m Cash $8.2 $9.6 1.4 Trade receivables Trade $10.9 $5.5 5.4 reflect the Receivables increased sales activity Inventories $13.6 $14.2 0.6 Total Current $
Slide 6: Sales by geography & product
For personal use only Sales by geography & product Asia, Australia & New Encapsulated Tuna oil Zealand have grown during leads sales revenue with 2016. encapsulated Algal oils and European and American other oils represented in markets provide new other products opportunities FY 2016 Geographi
Slide 7: An Update on Growth Platforms
For personal use only An Update on Growth Platforms Focus on infant formula customers and market Products and Market Development Research & Development 6
Slide 8: Growth Platform: Focus on infant formula customers
Focus on For personal use only Growth Platform infant formula customers Continued focus on the infant formula market and market The Chinese infant formula market continues to recover, with strong sales from Europe, Australia and New Zealand Traditional Nu-Mega customers sales are recovering, ref
Slide 9: Growth Platform: Products and Market Development
For personal use only Growth Platform Products and Market Developing new markets Development The first production run at Waikato in New Zealand is complete, with sales to new customers resulting Clover has established a distribution channel into the USA targeting the sports nutrition, food and w
Slide 10: Growth Platform: Research & Development
For personal use only Growth Platform Research & Development Research & Development Strengthened Clover employed two PhD scientists during 2016 to develop the next generation of products, with expertise in nutrition and encapsulation technology Clover has launched two new products; one targeting
Slide 11: FY2017 Outlook & Priorities
For personal use only FY2017 Outlook & Priorities Market development into the EU taking advantage of new regulations Develop new product applications into sports nutrition and wellness market segments Maintaining growth in Oceania, Asia and Europe Research & Development in collaboration with
Slide 12: Disclaimer
For personal use only Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe s